Page 106 - Read Online

Zhang et al. Cancer Drug Resist 2024;7:34 https://dx.doi.org/10.20517/cdr.2024.59 Page 17 of 20

101. Xie R, Cheng L, Huang M, et al. NAT10 drives cisplatin chemoresistance by enhancing ac4C-associated DNA repair in bladder
cancer. Cancer Res 2023;83:1666-83. DOI PubMed
102. Shi ZD, Hao L, Han XX, et al. Targeting HNRNPU to overcome cisplatin resistance in bladder cancer. Mol Cancer 2022;21:37. DOI
PubMed PMC
103. Wu J, Zhou Z, Li J, et al. CHD4 promotes acquired chemoresistance and tumor progression by activating the MEK/ERK axis. Drug
Resist Updat 2023;66:100913. DOI PubMed
104. Oh SJ, Lim JY, Son MK, et al. TRPV1 inhibition overcomes cisplatin resistance by blocking autophagy-mediated hyperactivation of
EGFR signaling pathway. Nat Commun 2023;14:2691. DOI PubMed PMC
105. Xiang L, Zeng Q, Liu J, et al. MAFG-AS1/MAFG positive feedback loop contributes to cisplatin resistance in bladder urothelial
carcinoma through antagonistic ferroptosis. Sci Bull 2021;66:1773-88. DOI PubMed
106. Tyagi A, Kaushal K, Chandrasekaran AP, et al. CRISPR/Cas9-based genome-wide screening for deubiquitinase subfamily identifies
USP1 regulating MAST1-driven cisplatin-resistance in cancer cells. Theranostics 2022;12:5949-70. DOI PubMed PMC
107. Limagne E, Nuttin L, Thibaudin M, et al. MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in
cancer cells. Cancer Cell 2022;40:136-52.e12. DOI PubMed
108. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence
and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424. DOI PubMed
109. Hong S, Zhang Y, Yu G, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as first-line therapy for recurrent or
metastatic nasopharyngeal carcinoma: final overall survival analysis of GEM20110714 phase III study. J Clin Oncol 2021;39:3273-
82. DOI PubMed PMC
110. Tang QN, Liu LT, Qi B, et al. Effect of concurrent chemoradiotherapy with nedaplatin vs cisplatin on the long-term outcomes of
survival and toxic effects among patients with stage II to IVB nasopharyngeal carcinoma: a 5-year follow-up secondary analysis of a
randomized clinical trial. JAMA Netw Open 2021;4:e2138470. DOI PubMed PMC
111. Zheng ZQ, Li ZX, Guan JL, et al. Long noncoding RNA TINCR-mediated regulation of acetyl-CoA metabolism promotes
nasopharyngeal carcinoma progression and chemoresistance. Cancer Res 2020;80:5174-88. DOI PubMed
112. Xue F, Cheng Y, Xu L, et al. LncRNA NEAT1/miR-129/Bcl-2 signaling axis contributes to HDAC inhibitor tolerance in
nasopharyngeal cancer. Aging 2020;12:14174-88. DOI PubMed PMC
113. Yang J, Xu J, Wang W, Zhang B, Yu X, Shi S. Epigenetic regulation in the tumor microenvironment: molecular mechanisms and
therapeutic targets. Signal Transduct Target Ther 2023;8:210. DOI PubMed PMC
114. Tang J, Wang X, Xiao D, Liu S, Tao Y. The chromatin-associated RNAs in gene regulation and cancer. Mol Cancer 2023;22:27.
DOI PubMed PMC
115. Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis
Primers 2020;6:92. DOI PubMed PMC
116. Sun S, Wu Y, Guo W, et al. STAT3/HOTAIR signaling axis regulates HNSCC growth in an EZH2-dependent manner. Clin Cancer
Res 2018;24:2665-77. DOI PubMed
117. Jiang Y, Guo H, Tong T, et al. lncRNA lnc-POP1-1 upregulated by VN1R5 promotes cisplatin resistance in head and neck squamous
cell carcinoma through interaction with MCM5. Mol Ther 2022;30:448-67. DOI PubMed PMC
118. Steuer CE, El-Deiry M, Parks JR, Higgins KA, Saba NF. An update on larynx cancer. CA Cancer J Clin 2017;67:31-50. DOI
PubMed
119. Li R, Chen S, Zhan J, et al. Long noncoding RNA FOXD2-AS1 enhances chemotherapeutic resistance of laryngeal squamous cell
carcinoma via STAT3 activation. Cell Death Dis 2020;11:41. DOI PubMed PMC
120. Pillai J, Chincholkar T, Dixit R, Pandey M. A systematic review of proteomic biomarkers in oral squamous cell cancer. World J Surg
Oncol 2021;19:315. DOI PubMed PMC
121. Tian T, Lv X, Pan G, et al. Long noncoding RNA MPRL promotes mitochondrial fission and cisplatin chemosensitivity via
disruption of pre-miRNA processing. Clin Cancer Res 2019;25:3673-88. DOI PubMed PMC
122. Filetti S, Durante C, Hartl D, et al; the ESMO Guidelines Committee. Thyroid cancer: ESMO Clinical Practice Guidelines for
diagnosis, treatment and follow-up. Ann Oncol 2019;30:1856-83. DOI PubMed
123. Shi L, Duan R, Sun Z et al. LncRNA GLTC targets LDHA for succinylation and enzymatic activity to promote progression and
radioiodine resistance in papillary thyroid cancer. Cell Death Differ 2023;30:1517-32. DOI PubMed PMC
124. Wang Y, Zhang X, Wang Z, et al. LncRNA-p23154 promotes the invasion-metastasis potential of oral squamous cell carcinoma by
regulating Glut1-mediated glycolysis. Cancer Lett 2018;434:172-83. DOI PubMed
125. Sang L, Ju HQ, Yang Z, et al. Mitochondrial long non-coding RNA GAS5 tunes TCA metabolism in response to nutrient stress. Nat
Metab 2021;3:90-106. DOI PubMed
126. Tan DSW, Chong FT, Leong HS, et al. Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and
modulates treatment response in squamous cell carcinoma. Nat Med 2017;23:1167-75. DOI PubMed
127. Zhang L, Meng X, Zhu XW, et al. Long non-coding RNAs in Oral squamous cell carcinoma: biologic function, mechanisms and
clinical implications. Mol Cancer 2019;18:102. DOI PubMed PMC
128. Nair L, Chung H, Basu U. Regulation of long non-coding RNAs and genome dynamics by the RNA surveillance machinery. Nat Rev
Mol Cell Biol 2020;21:123-36. DOI PubMed PMC
129. Zhang L, Xu X, Su X. Noncoding RNAs in cancer immunity: functions, regulatory mechanisms, and clinical application. Mol Cancer